Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT TO STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • October 7th, 2021 • 4D Pharma PLC • Pharmaceutical preparations • Texas
This AMENDMENT TO THE STRATEGIC COLLABORATION AGREEMENT (“Amendment”) is effective this 24th day of February 2021 (the “Amendment Effective Date”) by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”) and 4D PHARMA PLC, with a place of business located at 9 Bond Court Leeds LS1 2JZ, United Kingdom (“Company”). MD Anderson and Company are sometimes collectively referred to herein as the “Parties” and separately as a “Party.”
5th FloorService Agreement • October 7th, 2021 • 4D Pharma PLC • Pharmaceutical preparations
